» Articles » PMID: 35309879

Comparative Study on Depigmenting Agents in Skin of Color

Overview
Date 2022 Mar 21
PMID 35309879
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Skin lightening agents are popular in southern Asia, but there is dearth of evidence on their effectiveness on Fitzpatrick IV/V skin types. This study was designed to assess the depigmenting efficacy of commercially available and specifically formulated ointments using the Mexameter (MX 18).

Methods: This single center prospective study was performed to test five commercially available preparations (Eldopaque, Aziderm, Garnier Dark Spot Corrector, Ban a Tan Cream and Neostrata Pigment Lightening Gel) on 28 healthy female volunteers in Phase 1, while five single active ingredients in lipophilic dispersion (hydroquinone 4%, ascorbyl palmitate 1%, resveratrol 1% arbutin 5% and azelaic acid 20%) were tested on a different group of 26 healthy female volunteers in Phase 2. The test agents were applied twice a day for five days per week and continued for six weeks in both study phases. Weekly Mexameter measurements were obtained from test sites and negative controls.

Results: Significant hypopigmentation when compared to untreated controls was observed with Aziderm cream (<0.05, MWU) and the Neostrata Pigment Lightening Gel (<0.05, MWU). All formulated preparations showed significant reduction in pigmentation; however, only the arbutin (5%) containing formulation revealed significant attenuation of pigmentation in comparison to the inactive control (<0.05, MWU).

Conclusion: All applications containing active ingredients showed significant skin lightening; however, only arbutin was able to demonstrate significant diminution of pigmentation when compared to the inactive control.

Citing Articles

Comparative Studies on the Photoreactivity, Efficacy, and Safety of Depigmenting Agents.

Mota S, Rosa G, Barreto M, Garrido J, Sousa E, Cruz M Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256889 PMC: 10820089. DOI: 10.3390/ph17010055.


Antioxidant activity, anti-tyrosinase activity, molecular docking studies, and molecular dynamic simulation of active compounds found in nipa palm vinegar.

Chatatikun M, Tedasen A, Pattaranggoon N, Palachum W, Chuaijit S, Mudpan A PeerJ. 2023; 11:e16494.

PMID: 38025738 PMC: 10680452. DOI: 10.7717/peerj.16494.


Effect of (Poir.) Grande Essential Oil on Molecular Hallmarks of Skin Aging.

Alves-Silva J, Moreira P, Cavaleiro C, Pereira C, Cruz M, Salgueiro L Plants (Basel). 2023; 12(21).

PMID: 37960097 PMC: 10648677. DOI: 10.3390/plants12213741.


Anti-Melanogenic Effects of Root Extract via Downregulation of PKA/CREB and MAPK/CREB Signaling Pathways in B16F10 Cells.

Park S, Han N, Lee J, Lee J, An S, Bae S Plants (Basel). 2023; 12(21).

PMID: 37960022 PMC: 10648933. DOI: 10.3390/plants12213666.


Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Albzea W, AlRashidi R, Alkandari D, Sadan M, AlKandari A, Alkanderi J Cureus. 2023; 15(7):e41796.

PMID: 37457606 PMC: 10339666. DOI: 10.7759/cureus.41796.

References
1.
Weinstein G, McCullough J, Ross P . Cell proliferation in normal epidermis. J Invest Dermatol. 1984; 82(6):623-8. DOI: 10.1111/1523-1747.ep12261462. View

2.
Sccs , Degen G . Opinion of the Scientific Committee on Consumer safety (SCCS)--Opinion on the safety of the use of α-arbutin in cosmetic products. Regul Toxicol Pharmacol. 2015; 74:75-6. DOI: 10.1016/j.yrtph.2015.11.008. View

3.
Sarkar R, Chugh S, Garg V . Newer and upcoming therapies for melasma. Indian J Dermatol Venereol Leprol. 2012; 78(4):417-28. DOI: 10.4103/0378-6323.98071. View

4.
Farshi S . Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma. J Cosmet Dermatol. 2011; 10(4):282-7. DOI: 10.1111/j.1473-2165.2011.00580.x. View

5.
Solano F, Briganti S, Picardo M, Ghanem G . Hypopigmenting agents: an updated review on biological, chemical and clinical aspects. Pigment Cell Res. 2006; 19(6):550-71. DOI: 10.1111/j.1600-0749.2006.00334.x. View